EUCTR2009-015988-13-IT进行中（未招募）不适用
AN INTERNATIONAL MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND TRIAL TO EVALUATE DIFFERENT DOSE COMBINATIONS OF LERCANIDIPINE AND ENALAPRIL IN COMPARISON WITH EACH COMPONENT ADMINISTERED ALONE AND WITH PLACEBO IN PATIENTS WITH ESSENTIAL HYPERTENSION - REC 15/2375 IT CL 0336
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- RECORDATI
- 入组人数
- 990
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female, aged 18 - 75 years. - If females, the patient must be post-menopausal, surgically sterilized or, if child-bearing potential, non nursing and practicing an effective method of contraception throughout study duration (i.e. using oral or implanted contraceptive therapy or an intrauterine device). If naturally post-menopausal, the patient must not have had a menstrual period within 12 months prior to entry into the study. - Non-hospitalized patients. - Patients with essential hypertension (untreated or intolerant or not well controlled on current antihypertensive therapy), who are able to tolerate a drug-free period. - Office BP: sitting diastolic blood pressure (SDBP) between 100 and 109 mmHg (inclusive) and clinic sitting systolic blood pressure (SSBP) < 180 mmHg after a 2 week placebo run-in period. - Home BP: diastolic blood pressure at home >= 85 mmHg in the last week of the run-in period. - Normal ECG or with signs of LVH, first degree AV block, non specific ST-T wave changes, or other changes not considered clinically significant. - Satisfactory compliance to study medication (80-120%) during the run-in period. - Available to return to all scheduled visits and to comply with protocol requirements. - Written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Severe hypertension (SSBP >= 180 mmHg or SDBP >= 110 mmHg) - Patients with persistent differences in blood pressure between the two arms (>20 mmHg for SSBP or >10 mmHg for SDBP) on 3 immediately consecutive readings at Visit 1 - Known or suspected secondary hypertension (coarctation of the aorta, hyperaldosteronism, unilateral renal artery stenosis, pheochromocytoma, etc.) - History of cerebrovascular complications (TIA, stroke, hypertensive encephalopathy) History of cardiac complications (stable and unstable angina pectoris, myocardial infarction, by-pass, PTCA, congestive heart failure NYHA Class II-IV) - Hemodynamically significant valve disease, including aortic stenosis - Clinically significant ventricular or supraventricular arrhythmia; heart rate >100 beats/min - Type 1 or Type 2 diabetes on drug treatment - Severe renal or hepatic insufficiency - Clinically important abnormal laboratory findings during the run-in period: . Serum Creatinine >2 mg/dL . AST (SGOT) and/or ALT (SGPT) and/or GGT > 3 times the upper limit of normal . Fasting Plasma Glucose >= 126 mg/dL . Hemoglobin <10 g/dL. . Serum Potassium >5.5 mmol/L . Serum Sodium < 132 mmol/L - Any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigators assessment) - History of malignancy within the previous 5 years (skin cancer other than melanoma is an exception) - History of alcohol or drug abuse within the previous 2 years - History of allergy, hypersensitivity, intolerance or contraindication to dihydropyridine calcium antagonists or ACE inibitor - Use of prohibited concomitant medications, including vasoactive products, strong inhibitors of CYP3A4, ciclosporin and grapefruit juice (see Section 6.7 of study protocol) - Participation in another clinical trial within 30 days prior to entry into the present study - Any other condition, which, in the investigator`s judgement, renders the patient unable to complete the study or increases the risk to the patient or which prevents optimal participation in achieving the objectives of the study.
研究者
相似试验
已完成
不适用
A MULTICENTRE, INTERNATIONAL, RANDOMISED, PARALLEL GROUP, DOUBLE BLIND STUDY TO EVALUATE CARDIOVASCULAR SAFETY OF LINAGLIPTIN VERSUS GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK.-E11 Non-insulin-dependent diabetes mellitusNon-insulin-dependent diabetes mellitusE11PER-103-10Boehringer Ingelheim,246
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)EUCTR2006-006748-76-BGPfizer Ltd, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK219
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/AEUCTR2006-006748-76-GRPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH).MedDRA version: 8.1Level: LLTClassification code 10037400Term: Pulmonary hypertensionEUCTR2006-006748-76-NLPfizer Ltd. Ramsgate Road, Sandwich, Kent, UK284
进行中（未招募）
不适用
A MULTINATIONAL, MULTICENTRE, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF 1 MG, 5 MG AND 20 MG TID OF ORAL SILDENAFIL IN THE TREATMENT OF SUBJECTS AGED 18 YEARS AND OVER WITH PULMONARY ARTERIAL HYPERTENSION (PAH) - N/APulmonary arterial hypertension (PAH)EUCTR2006-006748-76-DKPfizer Ltd, Ramsgate Road, Sandwich, Kent UK219